Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ixabepilone may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when given together with radiation therapy to see how well it works in treating patients with high-risk stage III prostate cancer after surgery.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a phase I, dose-escalation study of ixabepilone followed by a phase II study.
Patients undergo adjuvant intensity-modulated radiation therapy once daily, 5 days a week, for 7-9 weeks. Patients also receive concurrent ixabepilone IV over 1 hour on days 1 and 8. Treatment with ixabepilone repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then annually for 6 years.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Diagnosis of adenocarcinoma of the prostate
Gleason score = 7 and post-operative PSA > 0 and ≤ 2 ng/mL OR Gleason score ≥ 8 and post-operative PSA ≥ 0 and ≤ 2 ng/mL
Pre-prostatectomy PSA available
PATIENT CHARACTERISTICS:
Zubrod (ECOG) performance status 0-1
ANC ≥ 2,000/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 8 g/dL
Total bilirubin < 1.5 times upper limit of normal (ULN)
AST and ALT < 2.5 times ULN
Alkaline phosphatase < 2.5 times ULN
Fertile patients must use effective contraception during and for 4 weeks after completion of study therapy
Patients with urinary incontinence waiting for stabilization of urinary function after prostatectomy allowed for up to 6 months
No CTCv4 peripheral neuropathy (motor or sensory) ≥ grade 1
No history of inflammatory colitis including Crohn disease or ulcerative colitis
No significant history of psychiatric illness
No other invasive malignancy within the past 3 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the oral cavity
No severe, active co-morbidity with any of the following:
Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
Transmural myocardial infarction within the past 6 months
Acute bacterial or fungal infection requiring IV antibiotics
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days
Immunocompromised patients or AIDS based upon current CDC definition
No history of hypersensitivity reactions to agents containing Cremophor® EL or its derivatives (e.g., polyoxyethylated castor oil)
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No prior pelvic radiotherapy or radiotherapy for another malignancy that encompasses ≥ 30% of major bone marrow-containing areas (e.g., pelvis or lumbar spine)
No prior hormonal therapy for prostate cancer
No other concurrent adjuvant antineoplastic therapy planned while on this protocol, including the following:
Cryotherapy
Hormonal therapy
Other chemotherapy for prostate cancer
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal